Presentations in European Society for Medical Oncology (ESMO) Congress 2025

SC-101, a Nectin-4-targeting peptide-drug conjugate (PDC), in patients with advanced or metastatic solid tumors: Results from dose-escalation study

EphA2 targeting PDC drug SC-102 received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA)

SC-101 granted ODD by FDA for the treatment of esophageal cancer

Conjustar biologics announced that SC-101 (Nectin-4-targeted PDC)  has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of esophageal cancer.

Conjustar announced the completion of ￥100 million Pre-A+ round of financing

Conjustar announced the completion of ￥100 million  Pre-A+ round of financing. This round of financing was led by Fosun health Capital New Drug Innovation Fund of Fosun Pharmaceutical, and co-invested by Hengqin Venture Capital and Shenzhen Qianhai Liyuan.